TX-PLANVIEW
10.11.2020 17:47:07 CET | Business Wire | Press release
TPG Capital, the private equity platform of global alternative asset firm TPG, and TA Associates, a leading global growth private equity firm, today announced that they have signed a definitive agreement to acquire Planview, a global leader in Portfolio Management and Work Management. TPG Capital and TA Associates will acquire the company for a purchase price of $1.6 billion. Planview’s existing majority shareholder, Thoma Bravo, will retain a minority interest in the company.
“We've spent more than three decades delivering innovation, driving the market forward, and reinventing ourselves. I truly believe that the best is yet to come for our customers and for Planview,” said Greg Gilmore, CEO of Planview. “We’re grateful for Thoma Bravo’s partnership over the last four years, and look forward to this next chapter as we accelerate our vision and continue to be a journey partner for our customers as they transform strategy to delivery.”
Planview has more than 30 years of experience partnering with organizations to help them connect strategy to delivery. The company provides a comprehensive platform that spans the spectrum of Portfolio Management and Work Management solutions that enable organizations to transform and accelerate on-strategy delivery at enterprise scale. Through the platform, organizations can build an innovation culture, realize agile at scale, make the project to product shift, and adapt to the changing world of work.
“The nature of work has been changing over the last several years as technology has enabled employees to be productive in ways that weren’t previously possible,” said Nehal Raj, Partner at TPG Capital. “This shift has only accelerated during the pandemic, and what is emerging is a new and enduring model of work that’s increasingly flexible, fragmented, and distributed. As more of our work lives transition to digital, organizations will require tools that provide executives visibility and connectivity across the entire enterprise. With Planview, we see an opportunity to partner with an innovative leader at the forefront of this new way of working. We look forward to supporting the company in its next chapter of growth.”
“We have followed Planview for over a decade and have been impressed by the company’s strong growth under Greg Gilmore’s leadership,” said Ashu Agrawal, a Managing Director at TA Associates. “We believe that Planview’s comprehensive portfolio and work management solutions provide continued market opportunities as they are uniquely positioned to help organizations effectively navigate and accelerate strategy to delivery. We look forward to partnering with the Planview management team during the company’s next growth phase, and are pleased to be investing alongside TPG and Thoma Bravo.”
“Planview is another example of Thoma Bravo working with existing management to implement our proprietary, operational approach to value creation while complementing the organic growth of the business with strategic and creative M&A,” said Holden Spaht, a Managing Partner at Thoma Bravo. “We’re proud of being a part of Planview’s transformation from an IT PPM provider to a broader Portfolio and Work platform with unique, dual leadership across Agile and traditional Project domains, and we believe Planview is well positioned to continue its growth amidst a changing world of work. We look forward to continuing to invest in a company with strong market leadership, a highly differentiated platform, and a clear ability to execute.”
UBS Investment Bank and Deutsche Bank Securities Inc. provided committed debt financing, and alongside Barclays and Jefferies LLC acted as financial advisors to TPG Capital and TA Associates. Ropes & Gray served as legal counsel to TPG Capital, and Goodwin Procter served as legal counsel to TA Associates. JP Morgan acted as financial advisor to Planview and Thoma Bravo, and Kirkland & Ellis served as legal counsel.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: https://www.planview.com/ .
About TPG
TPG is a leading global alternative asset firm founded in 1992 with approximately $83 billion of assets under management and offices in Austin, Beijing, Fort Worth, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, Singapore, and Washington, DC. TPG's investment platforms are across a wide range of asset classes, including private equity, growth equity, real estate, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com on Twitter @TPG .
About TA Associates
TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $33.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com .
About Thoma Bravo
Thoma Bravo is a leading private equity firm focused on the software and technology-enabled services sectors. With more than $70 billion in assets under management as of October 31, 2020, Thoma Bravo partners with a Company's management team to implement operating best practices, invest in growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings, with the goal of increasing the value of the business. The firm has offices in San Francisco and Chicago. For more information, visit www.thomabravo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005804/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
